GHRP-2 5MG

GHRP-2 5MG

Rating:
99 % of 100
$29.99

FREE Shipping for orders over $200

BACTERIOSTATIC WATER

For this product you will need: BACTERIOSTATIC WATER For reconstitution.

The chemicals/materials for sale here are intended for laboratory and research use only, unless otherwise explicitly stated. They are not intended for human ingestion or for use in products that may be ingested.
Sarms
Stacks
Research Liquids
Research Peptides
PDE5 Inhibitors
GLP-1
Diluents

What Is GHRP-2 5MG?

Growth hormone-releasing peptide 2 (GHRP-2) also called pralmorelin is a synthetic agonist of ghrelin and GH receptor. It is a secretagogue that binds with receptors in the pituitary gland and triggers the release of growth hormone (GH). It may slightly affect levels of cortisol, ACTH and prolactin. It also blocks the release of somatostatin and binds to the ghrelin receptor in the gut, which is involved in growth hormone release and appetite regulation.

GHRP-2 is known for enhancing muscle mass and strength and promoting better recovery from injuries. Further, it might be involved in appetite regulation, sleep improvement and age-related decline. This synthetic hexapeptide is not yet approved by FDA for clinical use. It also belongs to the list of drugs prohibited by WADA. On our website, GHRP-2 for sale is limited to educational and research purposes.

Structure Of GHRP-2 5MG

structure

From Pubchem

IUPAC Name:(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Synonym: Pralmorelin, 158861-67-7 and KP-102
Molecular Formula: C45H55N9O6
Molecular Weight: 818.0 g/mol
Sequence: AXAWFK
CAS Number: 158861-67-7
PubChem CID: 6918245

GHRP-2 5MG Uses In Research

1. GHRP-2 and Anti-Inflammatory Effect

Research shows that ghrelin exhibits anti-inflammatory properties and blocks proinflammatory cytokines like TNF-a by the growth hormone secretagogue receptor pathway. One study was conducted to assess the anti-inflammatory effect of GHRP-2 in LPS-treated rats. LPS administration in rats damages the liver cells and raises the level of transaminases, nitrates, and hepatic TNF-a. Researchers found that rats treated with GHRP-2 experienced the reduced effects of LPS on transaminases, nitrates and TNF-a. Further, the anti-inflammatory effect on non-parenchymal cells in the liver was observed [1].

In another study, the anti-inflammatory effect was observed in arthritis rats. Male wiser rats with arthritis-induced Freund’s adjuvant were either treated with saline water or GHRP-2 for eight days. The result found that GHRP-2 administration alleviated the external symptoms of arthritis in addition to reducing the levels of IL-6. Further researchers investigated if ghrelin or its agonist (GHRP-2) can modulate the release of IL-6 directly from immune cells. They incubated peritoneal macrophage cultures with GHRP-6 and found that it prevented IL-6 and nitrate release from cells under study. This indicates that GHRP-6 has an anti-inflammatory activity that might be mediated by ghrelin receptors present in immune cells [2].

2. GHRP-2 and Appetite

Ghrelin and its agonists are involved in appetite regulation. A clinical trial involving 10 prepubertal children was conducted to assess the effect of GHRP-2 on appetite. Participants received GHRP-2 900ug/kg twice a day for 12 months. The results found that 7 out of 10 patients reported an increase in appetite during the first 6 months of the study [3].

In another study, 7 healthy males received a subcutaneous infusion of GHRP-2 or saline water. Researchers found that participants who took GHRP-2 ate 26-46% more as compared to the control group [4].

3. GHRP-2 and Heart Health

GHRP-2 has been shown to promote heart health. One study conducted on myocardial stunning in a rabbit model found that GHRP-2 treatment for 14 days prevented diastolic dysfunction while recombinant human growth hormone didn’t show this effect [5].

Further, it can prevent cardiac remodeling following a heart attack and improve ventricular dysfunction. Research on the hamster model showed that GHRP-2 administration reduced myocardial fibrosis and slowed down the progression of left ventricular remodeling and dysfunction. Further, it was suggested that suppression of oxidative myocardial stress by GHRP-2 led to these beneficial effects [6].

4. GHRP-2 and Sleep

Research shows that GHRP-2 can extend the 2nd and 3rd stages of the sleep cycle by 50%. Furthermore, it has the potential to decrease the occurrence of deviations from regular sleep patterns by up to one-third [7]. On the contrary, one study didn’t find any significant association between GHRP-2 and slow-wave sleep [8].

5. GHRP2 and Muscle Health

One study in Yaks found that GHRP-2 injections caused an increase in myofiber diameter and area of skeletal muscle. This might be due to the increased secretion of growth hormone and IGF-1 by GHRP-2. Further, it promoted protein synthesis and upregulated the mRNA expression of IGF-1 and GH in the liver and skeletal muscles [9].

GHRP-2 has also been shown to prevent muscle proteolysis followed by injury. In one study, researchers investigated how GHRP-2 affects E3 ubiquitin ligase expression (associated with muscle breakdown) in rats with thermal injury. Administration of GHRP-2 through slow in vivo release for 24 hours via minipump effectively reduced the mRNA expression of IL-6, as well as the E3 ubiquitin ligases, MuRF-1 and MAFbx. Moreover, GHRP-2 decreased the total and myofibrillar protein breakdown in the rat EDL muscle caused by burns [10].

6. Current Status of GHRP-2

GHRP-2 is a synthetic agonist of the GH receptor and ghrelin. It might have a beneficial effect on sleep, appetite, heart and muscle mass. Despite its potential therapeutic properties, it has not yet been approved by the FDA. We need more studies to confirm its safety and efficacy in humans. GHRP-2 purchase is limited to educational and research institutions. Buy GHRP-2 for your research from Element Sarms for quality and authenticity.

Referenced Citations

  1. Granado, M., et al., GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. American Journal of Physiology-Endocrinology and Metabolism, 2008. 294(1): p. E131-E141.
  2. Granado, M., et al., Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology-Endocrinology and Metabolism, 2005. 288(3): p. E486-E492.
  3. Mericq, V., et al., Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab, 2003. 16(7): p. 981-5.
  4. Laferrère, B., C. Abraham, C.D. Russell, and C.Y. Bowers, Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. The Journal of Clinical Endocrinology & Metabolism, 2005. 90(2): p. 611-614.
  5. Weekers, F., E. Van Herck, J.r. Isgaard, and G. Van den Berghe, Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model**Presented in part at the Annual Meeting of the Belgian Endocrine Society, Brussels, November 20, 1999 (Young Investigator Award Winning abstract). This work was in part supported by a FUTURA Research Award (Voorzorgskas voor Geneesheren) 1998–1999 (to F.W.), research grants from the University of Leuven (OT 99/32 to G.V.d.B.), the Belgian Fund for Scientific Research (FWO G. 0144.00 & FWO G.3C05.95N) (to G.V.d.B.), and the Belgian Foundation for Research in Congenital Heart Diseases (to G.V.d.B. and F.W.). Endocrinology, 2000. 141(11): p. 3993-3999.
  6. Kato, Y., et al., Beneficial effects of growth hormone-releasing peptide on myocardial oxidative stress and left ventricular dysfunction in dilated cardiomyopathic hamsters. Circ J, 2010. 74(1): p. 163-70.
  7. Copinschi, G., et al., Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. 66(4): p. 278-86.
  8. Moreno-Reyes, R., et al., Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. American Journal of Physiology-Endocrinology and Metabolism, 1998. 274(5): p. E779-E784.
  9. Hu, R., et al., Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PLoS One, 2016. 11(2): p. e0149461.
  10. Sheriff, S., et al., Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides, 2009. 30(10): p. 1909-1913.

Certificate of Analysis (COA)

COA

High Performance Liquid Chromatography (HPLC)

COA

Mass Spectrometry (MS)

COA

GHRP-2 (also known as KP 102) is a synthetic hexapeptide Growth Hormone Releasing Peptide (GHRP), which acts on the hypothalamus and the pituitary gland to release growth hormone with a slight stimulator effect on Prolactin, ACTH and Cortisol levels. GHRP-2 is considered to be a true hGH secretagogue, meaning that it stimulates the body’s own secretion of hGH. Human Growth hormone has been shown in studies to promote lean body mass and reduce adiposity (fat). GHRP2 has demonstrated that it is very effective at stimulating GH production in research test subjects. It has a short half life with peak concentrations occurring around 15 minutes and not longer than 60 minutes after administration.
Write Your Own Review
You're reviewing:GHRP-2 5MG
Your Rating
Catalog
Product List
Sarms
Stacks
Research Liquids
Research Peptides
PDE5 Inhibitors
GLP-1
Diluents